ABBOTT LABORATORIES (NYSE:ABT) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Election of Directors
On February16, 2017, Daniel J. Starks was named to the Abbott
Board of Directors, effective immediately.
Item 5.03 Amendments to Articles of Incorporation or
Bylaws; Change in Fiscal Year
On February16, 2017, Abbott Laboratories Board of Directors
amended the first sentence of ArticleIII, Section2 of Abbotts
by-laws to provide that Abbotts Board of Directors shall consist
of twelve persons, effective as of February16, 2017. Abbotts
by-laws previously provided that the Board of Directors consisted
of eleven persons.
Item 9.01 Financial Statements and
Exhibits
|
ExhibitNo. |
|
Exhibit |
|
3.1 |
By-Laws of Abbott Laboratories, as amended and restated |
About ABBOTT LABORATORIES (NYSE:ABT)
Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The Company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Nutrition Products segment includes the sales of a line of adult and pediatric nutritional products. The Diagnostic Products includes the sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary, endovascular, structural heart, vessel closure and other medical device products. ABBOTT LABORATORIES (NYSE:ABT) Recent Trading Information
ABBOTT LABORATORIES (NYSE:ABT) closed its last trading session up +0.49 at 44.69 with 9,632,008 shares trading hands.
